@article{67f941ee372a49869b2d44d8ade9c197,
title = "Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests",
keywords = "Antibody dependent enhancement, Assessment, Risk benefit, Coronavirus, Ethics, Pharmacoepidemiology, Randomized clinical trials, Toxicity, Vaccines",
author = "Nir Eyal and Tobias Gerhard and Strom, {Brian L.}",
note = "Funding Information: The authors thank Alexander Guerrero, Marc Lipsitch, Monica Magalhaes, Bastian Steuwer, and anonymous reviewers for their helpful comments. NE{\textquoteright}s work is funded by Wellcome 208766/Z/17/Z (“Health policy trials: method, voice, and ethics”). NE, TG, and BLS declare having no relevant conflict of interest. NE declares that he serves on the board of advisors for challenge volunteer organization 1Day Sooner--an unpaid position. ",
year = "2021",
month = jun,
day = "11",
doi = "10.1016/j.vaccine.2021.04.056",
language = "English (US)",
volume = "39",
pages = "3455--3458",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "26",
}